Preliminary testing has shown in vitro and in vivo that antitumor activity
can be obtained with fusion proteins linking tumor-reactive monoclonal anti
bodies to cytokines, such as granulocyte macrophage colony-stimulating fact
or or interleukin 2 (IL-2), Preclinical and clinical testing of these reage
nts requires their in vitro and in vivo quantitation and pharmacokinetic ev
aluation. We have focused on the detection of a fusion protein which links
one human IL-2 molecule to the carboxy terminus of each heavy chain of the
tumor-reactive human-mouse chimeric anti-GD2 antibody, ch14.18. We have dev
eloped enzyme-linked immunosorbent assays (ELISAs) to evaluate intact tumor
-reactive fusion proteins, By these ELISAs we can reliably measure nanogram
quantities of intact ch14.18-IL-2 fusion protein and distinguish the intac
t protein from its components (ch14.18 and IL-2) in buffer, mouse serum, an
d human serum with specificity and reproducibility, The measurement of inta
ct ch14.18-IL-2 fusion protein is not confounded by free IL-2 or free ch14.
18 when 100 ng or less of total immunoglobulin per mi is used during the as
say procedure. Our results indicate that these ELISAs are suitable for prec
linical and clinical testing and with slight modifications are applicable t
o the analysis of a variety of other fusion proteins.